<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31682542</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>06</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>06</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1527-7755</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>38</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
          <ISOAbbreviation>J Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.</ArticleTitle>
        <Pagination>
          <StartPage>115</StartPage>
          <EndPage>123</EndPage>
          <MedlinePgn>115-123</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.19.01488</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with cytotoxic chemotherapy is highly effective for the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations; however, little is known about the efficacy and safety of this combination compared with that of standard therapy with EGFR- tyrosine kinase inhibitors alone.</AbstractText>
          <AbstractText Label="METHODS">We randomly assigned 345 patients with newly diagnosed metastatic NSCLC with EGFR mutations to gefitinib combined with carboplatin plus pemetrexed or gefitinib alone. Progression-free survival (PFS), PFS2, and overall survival (OS) were sequentially analyzed as primary end points according to a hierarchical sequential testing method. Secondary end points were objective response rate (ORR), safety, and quality of life.</AbstractText>
          <AbstractText Label="RESULTS">The combination group demonstrated a better ORR and PFS than the gefitinib group (ORR, 84% <i>v</i> 67% [<i>P</i> &lt; .001]; PFS, 20.9 <i>v</i> 11.9 months; hazard ratio for death or disease progression, 0.490 [<i>P</i> &lt; .001]), although PFS2 was not significantly different (20.9 <i>v</i> 18.0 months; <i>P</i> = .092). Median OS in the combination group was also significantly longer than in the gefitinib group (50.9 <i>v</i> 38.8 months; hazard ratio for death, 0.722; <i>P</i> = .021). The rate of grade â‰¥ 3 treatment-related adverse events, such as hematologic toxicities, in the combination group was higher than in the gefitinib group (65.3% <i>v</i> 31.0%); there were no differences in quality of life. One treatment-related death was observed in the combination group.</AbstractText>
          <AbstractText Label="CONCLUSION">Compared with gefitinib alone, gefitinib combined with carboplatin plus pemetrexed improved PFS in patients with untreated advanced NSCLC with EGFR mutations with an acceptable toxicity profile, although its OS benefit requires further validation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hosomi</LastName>
            <ForeName>Yukio</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morita</LastName>
            <ForeName>Satoshi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Kyoto University Graduate School of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sugawara</LastName>
            <ForeName>Shunichi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Sendai Kousei Hospital, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kato</LastName>
            <ForeName>Terufumi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fukuhara</LastName>
            <ForeName>Tatsuro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Miyagi Cancer Center, Natori, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gemma</LastName>
            <ForeName>Akihiko</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Nippon Medical School, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>Kazuhisa</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fujita</LastName>
            <ForeName>Yuka</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Asahikawa Medical Center, Asahikawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harada</LastName>
            <ForeName>Toshiyuki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Japan Community Health Care Organization Hokkaido Hospital, Sapporo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Minato</LastName>
            <ForeName>Koichi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Gunma Prefectural Cancer Center, Ota, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takamura</LastName>
            <ForeName>Kei</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Obihiro Kosei General Hospital, Obihiro, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hagiwara</LastName>
            <ForeName>Koichi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Jichi Medical University, Shimotsuke, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kobayashi</LastName>
            <ForeName>Kunihiko</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Saitama Medical University, Hidaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nukiwa</LastName>
            <ForeName>Toshihiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Tohoku University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Inoue</LastName>
            <ForeName>Akira</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Tohoku University School of Medicine, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>North-East Japan Study Group</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>UMIN-CTR</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>UMIN000006340</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Oncol</MedlineTA>
        <NlmUniqueID>8309333</NlmUniqueID>
        <ISSNLinking>0732-183X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>04Q9AIZ7NO</RegistryNumber>
          <NameOfSubstance UI="D000068437">Pemetrexed</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BG3F62OND5</RegistryNumber>
          <NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Clin Oncol. 2020 Jan 10;38(2):107-110</RefSource>
          <PMID Version="1">31774706</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068437" MajorTopicYN="N">Pemetrexed</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31682542</ArticleId>
        <ArticleId IdType="doi">10.1200/JCO.19.01488</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
